Please login to the form below

Not currently logged in
Email:
Password:

Bayer acquires rights to SciLin insulin

Bayer Schering Pharma has acquired to exclusive rights to market and distribute Bioton's SciLin insulin in China

Bayer Schering Pharma has acquired to exclusive rights to market and distribute Bioton's SciLin insulin in China.

The deal involves an up-front payment of €31m to the Polish insulin producer and will guarantee a secured supply of the insulin product for the next 15 years for exclusive commercial delivery by Bayer in the Chinese market.

Janusz R Guy, CEO of Bioton said: "With this agreement for long-term collaboration, Bioton has [realised] one of its strategic goals to develop its strong international position on growing insulin markets via alliances with leading pharmaceutical companies."

There are around 40 million diabetes sufferers in China and insulin has a projected annual growth rate of more than 40 per cent.

"Today, Bayer is already a top ranking international pharmaceutical company in China with our pharmaceutical Glucobay for treatment of type 2 diabetes being the most successful product. Through the planned distribution of SciLin, we will further supply patients suffering from diabetes, and will expand our position in this very promising growth market," said Andreas Fibig, CEO of Bayer Schering Pharma.

9th July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics